Trevena (TRVN) Competitors $1.75 -0.19 (-9.79%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRVN vs. SYRS, TXMD, CPIX, OSMT, CUE, FTLF, IPHA, VXRT, JMAC, and PBYIShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Syros Pharmaceuticals (SYRS), TherapeuticsMD (TXMD), Cumberland Pharmaceuticals (CPIX), Osmotica Pharmaceuticals (OSMT), Cue Biopharma (CUE), FitLife Brands (FTLF), Innate Pharma (IPHA), Vaxart (VXRT), Maxpro Capital Acquisition (JMAC), and Puma Biotechnology (PBYI). Trevena vs. Syros Pharmaceuticals TherapeuticsMD Cumberland Pharmaceuticals Osmotica Pharmaceuticals Cue Biopharma FitLife Brands Innate Pharma Vaxart Maxpro Capital Acquisition Puma Biotechnology Trevena (NASDAQ:TRVN) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Which has more volatility and risk, TRVN or SYRS? Trevena has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Do institutionals and insiders believe in TRVN or SYRS? 13.6% of Trevena shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is TRVN or SYRS more profitable? Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -105.93% Syros Pharmaceuticals N/A -1,419.05%-87.88% Does the MarketBeat Community prefer TRVN or SYRS? Trevena received 249 more outperform votes than Syros Pharmaceuticals when rated by MarketBeat users. Likewise, 70.32% of users gave Trevena an outperform vote while only 64.05% of users gave Syros Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTrevenaOutperform Votes61670.32% Underperform Votes26029.68% Syros PharmaceuticalsOutperform Votes36764.05% Underperform Votes20635.95% Do analysts prefer TRVN or SYRS? Trevena presently has a consensus price target of $125.00, indicating a potential upside of 7,042.86%. Syros Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 120.75%. Given Trevena's higher probable upside, equities research analysts clearly believe Trevena is more favorable than Syros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Syros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, TRVN or SYRS? Trevena has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$3.12M0.48-$40.29M-$55.50-0.03Syros Pharmaceuticals$9.94M6.11-$164.57M-$3.03-0.75 Does the media refer more to TRVN or SYRS? In the previous week, Syros Pharmaceuticals had 11 more articles in the media than Trevena. MarketBeat recorded 11 mentions for Syros Pharmaceuticals and 0 mentions for Trevena. Syros Pharmaceuticals' average media sentiment score of 0.80 beat Trevena's score of 0.00 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Trevena Neutral Syros Pharmaceuticals Positive SummarySyros Pharmaceuticals beats Trevena on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.68M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.0310.05116.1015.23Price / Sales0.48400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book-0.165.594.775.07Net Income-$40.29M$153.56M$119.06M$225.46M7 Day Performance-12.06%0.13%0.80%0.37%1 Month Performance-53.33%15.23%5.65%3.57%1 Year Performance-87.70%41.14%36.75%29.43% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena1.371 of 5 stars$1.75-9.8%$125.00+7,042.9%-87.1%$1.51M$3.12M-0.0340Gap UpSYRSSyros Pharmaceuticals4.6718 of 5 stars$2.00-3.4%$5.00+150.0%-5.2%$53.46M$4.15M-0.47120Earnings ReportAnalyst ForecastNews CoverageGap DownTXMDTherapeuticsMD0.8331 of 5 stars$1.59+0.6%N/A-26.1%$18.34M$996,000.000.00420CPIXCumberland Pharmaceuticals0.5882 of 5 stars$1.22-1.6%N/A-37.1%$17.31M$37.79M-1.6780Upcoming EarningsAnalyst ForecastOSMTOsmotica PharmaceuticalsN/AN/AN/AN/A$69.47M$177.88M-0.70302CUECue Biopharma4.6538 of 5 stars$1.48-5.1%$5.00+237.8%-24.8%$71.99M$8.30M-1.5360Positive NewsGap UpHigh Trading VolumeFTLFFitLife Brands3.8986 of 5 stars$31.71-1.6%$40.00+26.1%+44.0%$145.80M$60.68M19.7020Negative NewsIPHAInnate Pharma2.8043 of 5 stars$1.80-2.7%$11.50+538.9%-13.6%$145.75M$66.71M0.00220Gap DownVXRTVaxart1.9014 of 5 stars$0.82+6.5%$3.00+264.4%+19.2%$145.59M$15.65M-1.79109Upcoming EarningsNews CoverageJMACMaxpro Capital AcquisitionN/A$0.14flatN/A-85.1%$145.16MN/A0.002,021Gap DownHigh Trading VolumePBYIPuma Biotechnology2.4848 of 5 stars$2.95+5.4%$7.00+137.3%+11.3%$144.70M$235.60M15.53185Upcoming EarningsAnalyst UpgradeNews Coverage Related Companies and Tools Related Companies SYRS Alternatives TXMD Alternatives CPIX Alternatives OSMT Alternatives CUE Alternatives FTLF Alternatives IPHA Alternatives VXRT Alternatives JMAC Alternatives PBYI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRVN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
